1<121362 p 1 of 3 NeoCoil

N27 W23910A Paul Rd Pewaukee, WI 53072 Direct: (262) 347-1250 Fax: (262) 347-1251

# 5. Abbreviated 510(k) Summary

5.1. Applicant NeoCoil, LLC N27 W23910A Paul Rd Pewaukee, WI 53072

5.2. Contact
Steven Nichols
Chief Operating Officer
262-347-1250 (office)
261-347-1251 (fax)
steve.nichols@neocoil.com

5.3. Preparation Date 04/13/2012

5.4. Name of Device

Proprietary Name:

1.5T 16ch Flex SPEEDER Coil

Common Name:

Magnetic Resonance Specialty Coil
21 CFR 892.1000, Product Code MOS

Classification:

#### 5.5. Model Numbers

NeoCoil Model Number	NeoCoil Model Name	Toshiba Model
NC043000		MJAJ-227A/S1 (Japan)
	1.5T 16ch Flex SPEEDER Coil Large	MJAJ-227A/J1 (USA)
		MJAJ-227A/E1 (Europe)
NC042000		MJAJ-217A/S1 (Japan)
	1.5T 16ch Flex SPEEDER Coil Medium	MJAJ-217A/J1 (USA)
		MJAJ-217A/E1 (Europe)

## 5.6. Device Description

The NeoCoil 1.5T 16ch Flex SPEEDER is a receive-only phased array coil system designed to provide high resolution imaging for the upper and lower extremities, chest, abdomen, pelvis, head, neck, and spine. The system is compatible with 2D, 3D, parallel and isotropic imaging, as well as, coil signal intensity correction. The system consists of:

- Two formable, flexible and detachable antennae of different size that can be wrapped or orientated flat, in order to accommodate various anatomic shapes and sizes.
- Optional accessories designed for patient comfort and reduced motion artifacts.

The NeoCoil 1.5T 16ch Flex SPEEDER coil is tuned to receive RF frequency corresponding to the proton precession in a 1.5 tesla magnetic field, which is governed by the Larmor equation.

# 5.7. Predicate Device

1.5T GEM Flex Coil (K113474)

#### 5.8. Comparison to Predicate

The NeoCoil 1.5T 16ch Flex SPEEDER coils are identical in physical, performance, design and material characteristics to the legally marketed device, the 1.5T GEM Flex Coil, K113474, as cleared on 03/16/2012.

© 2012 NeoCoil, LLC	•
·	

K121362

N27 W23910A Paul Rd Pewaukee, WI 53072 Direct: (262) 347-1250 Fax: (262) 347-1251



The differences introduced in this submission include:

- Electrical interface with the MRI scanner, in order to ensure compatibility.
- Coil cable, cable covering and connector, in order to satisfy Toshiba requirements and achieve MRI scanner compatibility.
- Minor dimensional changes compared to the GEM Flex arrays, resulting from the elimination of the GEM Flex interface module.

The Indications for Use are consistent with the capabilities of the 1.5T GEM Flex Coil.

Clinical testing demonstrates that the differences in the devices do not affect the safety and/or the effectiveness of the device when used as labeled.

#### 5.9. Indications for Use

To be used in conjunction with Toshiba Magnetic Resonance Scanners with DL96 connectors to produce diagnostic images of the upper and lower extremities, chest, abdomen, pelvis, head, neck, and spine that can be interpreted by a trained physician.

## 5.10. Intended Use

Intended use of the 1.5T 16ch Flex SPEEDER Coil is identical to that of routine MR imaging; specifically to produce diagnostic images of the upper and lower extremities, chest, abdomen, pelvis, head, neck, and spine.

Use of the device in conjunction with an MRI scanner is unchanged.


#### 5.11. Testing

The following data has been submitted, referenced or relied on to demonstrate that the 1.5T 16ch Flex SPEEDER Coil is safe and effective. The device's performance meets the requirements of pre-defined acceptance criteria and intended uses.

Performance testing - Bench:

Test	Pass/Fail Criteria	Result		
Max B1 in first fault conditions	Pre-defined performance standards	Pass: Coil does not arc or show any signs of voltage breakdown.		
Surface Temperature in normal and first fault conditions	Pre-defined performance standards	Pass: RF heating is not greater than 39 <sup>o</sup> C in normal or first fault conditions.		
NEMA MS 6-2008	Pre-defined performance standards	Pass: SNR and Uniformity are consistent with the requirements for indications for use.		
Unplugged Surface Temperature  Acceptable level of risk		Pass: Surface temperature rise results in acceptable residual risk after mitigation.		

N27 W23910A Paul Rd Pewaukee, WI 53072 Direct: (262) 347-1250 (262) 347-1251 Fax:



Published Standards testing:

Standard	Purpose
IEC 60601-1	Electromechanical safety
IEC 60601-1-2	ESD
IEC 60601-2-33	Electromechanical safety
ISO 10993-1	Biocompatibility

## Performance testing - Clinical:

Clinical data submitted exhibits a mix of scanner configurations, pulse sequences, imaging options, field of view and anatomy in the axial, sagittal and coronal planes as recommended in the FDA guidance, Guidance for the Submission Of Premarket Notifications for Magnetic Resonance Diagnostic Devices.

No adverse events were reported during clinical performance testing; the 1.5T 16ch Flex SPEEDER Large and 1.5T 16ch Flex SPEEDER Medium coils demonstrated performance adequate to support the Indications for Use.

#### Conclusion

This submission demonstrates that the Indications for Use are in line with the predicate device to produce diagnostic images of the upper and lower extremities, chest, abdomen, pelvis, head, neck, and spine and are as safe and effective as the predicate device. As such, 1.5T 16ch Flex SPEEDER coils are equivalent to their predicate, 1.5T GEM Flex Coil, K113474.

© 2012 NeoCoil, LLC		•		
•				



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

Mr. Steven Nichols Chief Operating Officer NeoCoil, LLC N27 W23910A Paul Road PEWAUKEE WI 53072

JUN 1 5 2012

Re: K121362

Trade/Device Name: 1.5T 16ch Flex SPEEDER

Regulation Number: 21 CFR 892.1000

Regulation Name: Magnetic resonance diagnostic device

Regulatory Class: II Product Code: MOS Dated: April 13, 2012 Received: May 7, 2012

# Dear Mr. Nichols:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely Yours

Janine M. Morris

Acting Director

Division of Radiological Devices
Office of In Vitro Diagnostic Device

Evaluation and Safety.

Center for Devices and Radiological Health

**Enclosure** 

# **Indications for Use**

510(k) Number (if known):		
Device Name: 1.5T 16ch Flex SPEEDI	<u>ER</u>	
Indications for Use:		
	extremities, chest	e Scanners with DL96 connectors to produce , abdomen, pelvis, head, neck and spine that
· ·		
Prescription Use X (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW 'NEEDED)	THIS LINE-CO	NTINUE ON ANOTHER PAGE OF
Concurrence of CDRH, Office of In Vi	itro Diagnostic Γ	Devices (OIVD)
July Officer		

510(k) 1121362

Evaluation and Safety.

Office of In Vitro Diagnostic Device